You are here

Article Text

Article menu
Download PDFPDF
Original article
Markers of apoptosis in stage IB squamous cervical carcinoma
  1. G Van de Putte1,
  2. R Holm2,
  3. A K Lie2,
  4. M Baekelandt1,
  5. G B Kristensen1
  1. 1Department of Gynaecological Oncology, The Norwegian Radium Hospital, Montebello, 0310 Oslo, Norway
  2. 2Department of Pathology, The Norwegian Radium Hospital
  1. Correspondence to:
 Dr G Van de Putte
 Department of Gynaecological Oncology, The Norwegian Radium Hospital, Montebello, 0310 Oslo, Norway; gregg.marijkepandora.be

Abstract

Aims: To examine the prognostic relevance of the expression of the Bcl-2, Bcl-xL, and Bax proteins in stage IB squamous cervical carcinoma (SCC).

Methods: In total, 220 patients who underwent radical hysterectomy and bilateral lymphadenectomy at the Norwegian Radium Hospital for stage IB SCC between 1987 and 1993 were studied. Immunohistochemistry using monoclonal antibodies against Bcl-2, Bcl-xL, and Bax was used to examine protein expression. Ten patients who underwent hysterectomy for uterine prolapse served as controls.

Results: Cytoplasmic expression of Bcl-2, Bcl-xL, and Bax was low (< 5% positive cells) in 159 of 220 (73%), 193 of 220 (87%), and 39 of 220 (18%) tumours, respectively, and high (⩾ 5% positive cells) in 61 of 220 (27%), 27 of 220 (13%), and 181 of 220 (82%) tumours, respectively. In univariate analysis, all classic clinicopathological parameters but none of the investigated proteins were associated with prognosis. In multivariate analysis, only deep stromal invasion was independently related to survival.

Conclusion: Bcl-2, Bcl-xL, and Bax were not independently associated with prognosis in stage IB SCC.

  • SCC, squamous cervical carcinoma
  • Bcl-2
  • Bcl-xL
  • and Bax
  • immunohistochemistry
  • prognosis
  • cervical neoplasms
  • retrospective studies
  • biological markers

https://doi.org/10.1136/jcp.2004.021220

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes